Ceftriaxone Sodium
- Product NDC
- 50090-2444
- 11-digit product format
- 500902444
- Labeler code
- 50090
- Product ID
- 50090-2444_bcf28f1c-6595-4c9d-914c-3f6fc09a8cf9
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Ceftriaxone Sodium
- Dosage form
- INJECTION, POWDER, FOR SOLUTION
- Route
- INTRAMUSCULAR; INTRAVENOUS
- Labeler
- A-S Medication Solutions
- Application
- ANDA065169
- Marketing category
- ANDA
- Marketing start
- 2005-05-09
- Substance
- CEFTRIAXONE SODIUM
- Active strength
- 250 mg/1
- Pharmacologic classes
- Cephalosporin Antibacterial [EPC], Cephalosporins [CS]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A065169-001 | CEFTRIAXONE | CEFTRIAXONE SODIUM | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 |
| A065169-002 | CEFTRIAXONE | CEFTRIAXONE SODIUM | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 |
| A065169-003 | CEFTRIAXONE | CEFTRIAXONE SODIUM | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 |
| A065169-004 | CEFTRIAXONE | CEFTRIAXONE SODIUM | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A065169-001 | AP |
| A065169-002 | AP |
| A065169-003 | AP |
| A065169-004 | AP |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-18 06:07:40 | 2026-07 | A065169-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A065169-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A065169-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A065169-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A065169-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A065169-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A065169-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A065169-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A065169-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A065169-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A065169-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A065169-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A065169-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A065169-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A065169-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A065169-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A065169-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A065169-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A065169-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A065169-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A065169-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A065169-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A065169-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A065169-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A065169-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A065169-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A065169-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A065169-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A065169-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A065169-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A065169-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A065169-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A065169-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A065169-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A065169-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A065169-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A065169-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A065169-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A065169-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A065169-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | RS | 2005-05-09 | d8e5a09893c0… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-18 06:07:40 | 2026-07 | A065169-001 | AP | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A065169-002 | AP | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A065169-003 | AP | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A065169-004 | AP | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A065169-001 | AP | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A065169-002 | AP | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A065169-003 | AP | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A065169-004 | AP | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A065169-001 | AP | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A065169-002 | AP | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A065169-003 | AP | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A065169-004 | AP | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A065169-001 | AP | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A065169-002 | AP | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A065169-003 | AP | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A065169-004 | AP | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A065169-001 | AP | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A065169-002 | AP | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A065169-003 | AP | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A065169-004 | AP | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A065169-001 | AP | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A065169-002 | AP | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A065169-003 | AP | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A065169-004 | AP | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A065169-001 | AP | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A065169-002 | AP | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A065169-003 | AP | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A065169-004 | AP | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A065169-001 | AP | 1 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A065169-002 | AP | 1 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A065169-003 | AP | 1 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A065169-004 | AP | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A065169-001 | AP | 1 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A065169-002 | AP | 1 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A065169-003 | AP | 1 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A065169-004 | AP | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A065169-001 | AP | 1 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A065169-002 | AP | 1 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A065169-003 | AP | 1 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A065169-004 | AP | 1 | d8e5a09893c0… |
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Ceftriaxone Sodium
- Listing expiration
- 2026-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| CEFTRIAXONE SODIUM | 250 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 023Z5BR09K | Internal UNII lookup |
Harmonized RxCUI identifiers#
| Identifier | FDA.report destination |
|---|---|
| 309092 | Internal RxNorm lookup |
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| ff8e830a-c288-46fb-9e19-ec2017943c07 | Available on FDA.report |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 67ae10d0-6c6a-4d52-a629-da83321859b9 | Product name | 3 | 20190201 |
| 01b0d089-049b-4c6d-8dfe-1bffad9be307 | Product name | 2 | 20180807 |
| 2d5083fe-71de-4fce-8d67-e9049cba775c | Product name | 1 | 20150107 |
| 1037f4ca-3bea-c9c4-2af4-fa6387b0e81e | Product name | 1 | 20140508 |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 50090-2444-0 | 2023-02-07 | C162847 | 48780-1 | f386c64a-075e-0266-e053-dadaa90a7c1a | Ceftriaxone for Injection, USP Rx Only |
| 50090-2444-0 | 2023-01-30 | C162847 | 48780-1 | f386c64a-075e-0266-e053-dadaa90a7c1a | Ceftriaxone for Injection, USP Rx Only |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 50090-2444-0 | Ceftriaxone Sodium | 10 in 1 CARTON | INJECTION, POWDER, FOR SOLUTION | 10 | 16 | |
| 50090-2444-0 | Ceftriaxone Sodium | 1 in 1 VIAL, SINGLE-USE | INJECTION, POWDER, FOR SOLUTION | 1 | 16 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 50090-2444-0 | EA - Each | 50090-2444 | 48037adf-6770-4fe7-8cb8-a0781cffbac6 | 1 | 2019-03-12 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 50090-2444 | CEFTRIAXONE SODIUM INJECTION, POWDER, FOR SOLUTION [A-S MEDICATION SOLUTIONS] | 16 | Current NDC, Legacy NDC, 2 package rows | 20240201_ff8e830a-c288-46fb-9e19-ec2017943c07.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Sportpharm LLC | ddbc3bf6-5bab-4851-ae5a-ef263cd8f255 | 2026-07-23 | Warnings, Adverse reactions | 065169 ANDA065169 |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | REMEDYREPACK INC. | 9c801096-ca61-4b29-a1e1-5f7e7813b191 | 2026-02-06 | Warnings, Adverse reactions | 065169 ANDA065169 |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Hospira, Inc | 19141ccd-e66c-49a2-a794-0616028495a7 | 2026-01-19 | Warnings, Adverse reactions | 065169 ANDA065169 |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Hospira, Inc | 03283208-8616-4117-9d2b-aa8046017a4f | 2026-01-19 | Warnings, Adverse reactions | 065169 ANDA065169 |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Sandoz Inc | de028434-46cf-44f6-8ac6-889c7c6943b3 | 2025-02-27 | Warnings, Adverse reactions | 065169 ANDA065169 |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | A-S Medication Solutions | b642877e-0d36-4218-afe9-0a39f35b571d | 2024-03-27 | Warnings, Adverse reactions | 065169 ANDA065169 |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | A-S Medication Solutions | 1aa0a4ee-1b39-4c3d-a7a3-33dded6fe28c | 2024-01-31 | Warnings, Adverse reactions | 065169 ANDA065169 |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | A-S Medication Solutions | ff8e830a-c288-46fb-9e19-ec2017943c07 | 2024-01-31 | Warnings, Adverse reactions | 065169 ANDA065169 50090-2444 |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Proficient Rx LP | a25ab5ea-c46d-4562-8f7e-0ccffc2ab069 | 2022-10-01 | Warnings, Adverse reactions | 065169 ANDA065169 |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 309092 | cefTRIAXone 250 MG Injection | PSN | ff8e830a-c288-46fb-9e19-ec2017943c07 | 16 |
| 309092 | ceftriaxone 250 MG Injection | SCD | ff8e830a-c288-46fb-9e19-ec2017943c07 | 16 |
| 309092 | ceftriaxone 250 MG (as ceftriaxone sodium) Injection | SY | ff8e830a-c288-46fb-9e19-ec2017943c07 | 16 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|
| 50090-2444-0 | 50090244400 | 10 VIAL, SINGLE-USE in 1 CARTON (50090-2444-0) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, SINGLE-USE | 2016-08-08 | 0000-00-00 | No | No | Current |